Characterisation of an anti-glycan monoclonal antibody against ovarian cancer

File Description SizeFormat 
Choo-SFM-2016-PhD-Thesis.pdfThesis21 MBAdobe PDFView/Open
Title: Characterisation of an anti-glycan monoclonal antibody against ovarian cancer
Authors: Choo, Sern Farh Matthew
Item Type: Thesis or dissertation
Abstract: Ovarian cancer is a deadly disease that has been associated with changes in glycans. Therefore, anti-glycan monoclonal antibodies (mAb) have the potential to selectively kill or retard chemoresistant tumours. However, the interactions between mAb and glycan epitopes are difficult to characterise due to the specialised tools and expertise required. Recently, our group discovered mAb-A4, a novel mAb found to bind and kill hESC and multiple cancer types including OC but not normal cell lines. Further analysis revealed that mAb-A4 binding was glycan dependent. Thus, it was hypothesised that mAb-A4 was targeting an oncofetal glycan antigen specific to stem and OC cells versus normal cells. In this thesis, the mAb-A4 glycan antigen in OC cell lines was investigated by advanced high-sensitivity mass spectrometry (MS), enzymatic digestion, glycan microarray and siRNA knockdown. Importantly, a novel adaptation allowed the detailed characterisation of polylactosamine termini from OC cell lines by MS. MS detected Type 1 and H Type 1 glycans on OC cells, and their soluble forms could also block mAb-A4 binding to cells in flow cytometry and Western blot. Furthermore, siRNA-mediated knockdown of B3GALT5 in SKOV3 demonstrated that the antigen was dependent on the Type 1 structure. It was concluded that mAb-A4 specifically recognises oncofetal Type 1 and H Type 1 on OC and hESC, and that this recognition was novel compared to other anti-H Type 1 mAbs such as anti-SSEA-5, 17-206, RAV12 and HESCA-2. Currently, the role of Type 1 and H Type 1 in OC is unknown, but these findings warrant further investigation into the purpose and prevalence of these glycan biomarkers in disease progression. The methods developed in this thesis enable the characterisation of additional anti-glycan mAbs and cancer cell lines, facilitating the discovery of novel biomarkers and therapies against cancer.
Content Version: Open Access
Issue Date: Jan-2016
Date Awarded: May-2016
URI: http://hdl.handle.net/10044/1/60081
Supervisor: Dell, Anne
Haslam, Stuart
Choo, Andre
Sponsor/Funder: Singapore. Agency for Science, Technology and Research
Department: Life Sciences
Publisher: Imperial College London
Qualification Level: Doctoral
Qualification Name: Doctor of Philosophy (PhD)
Appears in Collections:Life Sciences PhD theses



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Creative Commonsx